Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Chai Foundation For Medical Research & Life Extension Inc. operates within the Biotechnology & Pharmaceuticals technology area with a singular focus in its current prosecution. The data shows 1 pending office action, which constitutes the entirety of the company's active engagement with the patent office. This action is being handled by 1 distinct examiner, suggesting a direct and centralized line of communication. Furthermore, the portfolio is situated within 1 distinct art unit, reflecting a narrow technical classification for the pending claims and a lack of jurisdictional diversity.
The busiest examiner for this portfolio is ZEMAN, ROBERT A, who is currently assigned 1 busiest examiner pending office action. Since there is only 1 pending office action total, ZEMAN, ROBERT A is the only examiner currently reviewing the company's work. This means the prosecution outcome is tied to the specific scrutiny of this 1 distinct examiner. For a practitioner, the alignment of 1 distinct art unit and 1 distinct examiner indicates that there is no current complexity arising from multiple simultaneous reviews or differing art unit standards. This allows the applicant to focus entirely on the active matter without the distraction of other filings.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ZEMAN, ROBERT A | 1 | 54.3% | +27.7% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17896847 | COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATMENT OR PREVENTION OF CONDITIONS ASSOCIATED WITH HYPERPROLIFERATIVE CELLULAR DIVISION, DIABETES, IMMUNODEFICIENCY DISEASES, ALZHEIMER'S DISEASE OR AUTOIMMUNE DISEASES, AND TESTING SYSTEM AND METHOD | ZEMAN, ROBERT A | 26d |
| Art Unit | Apps |
|---|---|
| 1645 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17896847 | COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATMENT OR PREVENTION OF CONDITIONS ASSOCIATED WITH HYPERPROLIFERATIVE CELLULAR DIVISION, DIABETES, IMMUNODEFICIENCY DISEASES, ALZHEIMER'S DISEASE OR AUTOIMMUNE DISEASES, AND TESTING SYSTEM AND METHOD | ZEMAN, ROBERT A | 1645 | §112 | Non-Final OA | 26d | Pending | Aug 26, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial